METHOD OF RISK EVALUATION OF METABOLIC SYNDROME IN PATIENTS WITH CHRONIC CHOLECYSTITIS Russian patent published in 2010 - IPC A61B10/00 G01N33/66 G01N33/92 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to gastroenterology and cardiology, can be used in medical institutions for determination of severity level of metabolic disorders and risk of metabolic syndrome in the patients suffering chronic cholecystitis. For risk evaluation of metabolic syndrome in the patients with chronic cholecystitis by the severity of immune-metabolic disorders, the following significant diagnostic characters are used: fasting glucose, apoprotein atherogenicity coefficient (apoB/anoAl), high density lipoprotein cholesterol, T-helpers and T-suppressors ratio, phagocytic index. The derived values are entered in an arithmetic formula to evaluate the risk of metabolic syndrome by the severity level of immune-metabolic disorders by total value expressed in standard units.

EFFECT: method facilitates work of a doctor, allows to evaluate the patient's status in a relatively short time, to predict the risk of metabolic syndrome and to prescribe the well-timed therapy to prevent the progression of metabolic syndrome and cardiovascular complications in the patients with chronic cholecystitis.

1 tbl, 3 ex